Having trouble viewing this email? View in your browser.

16 March 2021

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.


ECCMID moves fully online

On 10 March 2021, the ESCMID Executive Committee, after very careful deliberation and consideration, made the decision that the 31st ECCMID, taking place from 9 – 12 July 2021, will be held fully online.

We are very much looking forward to our first ever fully online ECCMID, and to having you join us for this exciting new chapter in ECCMID history. The usual ECCMID scientific symposia, keynote lectures, meet-the-expert sessions and educational workshops will all be present, in addition to exciting new ECCMID formats tailor-made for online delivery.

› Read more

New ESCMID online postgraduate course now available for registration

The ESCMID online postgraduate Parasitology Workshop is now available for registration.

This interactive online workshop will provide a fun scientific window into the parasitic infections of importance for routine clinical practice in European countries. The online workshop will interest clinical microbiologists, ID physicians, microbiologists, clinical scientists, biomedical scientists, travel medicine experts and researchers interested and/or working in parasitology.

Find the programme flyer and link for registration for this and many other ESCMID online courses on the ESCMID online courses website.

› Read more

New ECCMID online sessions: prepare your team for the Escape Room

New for ECCMID 2021, the ECCMID Escape Room is a team activity for groups of 4-8 people (optimal group size 6 people) to meet online to collect clues and solve an interactive clinical case within a one hour time limit. Five slots are available on each day of ECCMID (9 – 12 July), so be sure to form your team soon!

Registration will open in April 2021, but get your group together today to prepare for your place in this new ECCMID activity. The case, the clues and the clock are waiting for you!

› Read more


Have you watched the new ESCMID Vlogs yet?

Listen to the thoughts of members of the ESCMID community as they give their thoughts on the current state of the ID/CM community, COVID-19 and ECCMID. 

More Vlogs are still to come on the ESCMID YouTube Channel.

› Read more

*SAVE THE DATE* - EMA Virtual Veterinary Big Data Stakeholder Forum on 1-2 June 2021

EMA is pleased to announce a “Veterinary Big Data Stakeholder Forum” to be held virtually on 1-2 June 2021.

Inspired by the implementation of the Veterinary Medicines Regulation (EU) 2019/6 and in line with the European Network of Medicines Agency (EMAN) Strategy to 2025, EMA would like to open a conversation on the opportunities that new digital technologies offer in the Veterinary medicines domain.

As part of the HMA-EMA joint Big Data Task Force activities, this event intends to engage all relevant stakeholders to share their experience and views on the current use of “Big Data” and future needs and opportunities.

It will bring together regulators, the pharmaceutical industry, farm management system providers, academia, consumers and practitioners, to:

  • build awareness on the use of innovative digital technologies in the veterinary regulatory environment;
  • share needs, ambitions and opportunities;
  • inspire future activities shaping the development of the European Veterinary Big Data Strategy.`

For further information, please see the draft programme overview.

For any questions on the event, please contact directly Vet-bigdata@ema.europa.eu

› Read more

ESCMID YouTube Channel: Catch the Websymposia!

Have you subscribed to the ESCMID YouTube channel? Find Vlogs, ECCVID sessions, as well as the replays of the COVID-19 Websymposia available for on-demand viewing.

Visit the ESCMID YouTube channel to view and subscribe!

› Read more

CMI highlight: COVID-19 is associated with an increased risk of bradycardia.

Using the WHO Global Individual Case Safety Reports database 302 cardiac effects were found, including 94 bradycardia (31%) among the 2,603 reports with remdesivir prescribed in COVID-19 patients. Most of reports were serious (75, 80%) and in 16 reports (17%) evolution was fatal. Compared with hydroxychloroquine, lopinavir/ritonavir, tocilizumab or glucocorticoids, the use of remdesivir was associated with an increased risk of reporting bradycardia (ROR 1.65; 95% CI 1.23, 2.22). Consistent results were observed in other sensitivity analyses. According to the authors, this study suggests that the use of remdesivir is significantly associated with an increased risk of reporting bradycardia and serious bradycardia when compared with the use of with hydroxychloroquine, lopinavir/ritonavir, tocilizumab or glucocorticoids, a result in line with pharmacodynamic properties of the remdesivir.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.